
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

